,5 Although new approaches have emerged during past decades in the treatment of lung cancer patients, including reagents that target epidermal growth factor receptor (EGFR) mutation, alkaline phosphatase (ALK) fusion, and programmed death ligand 1 (PD-L1) immunotherapy,6, 7, 8, 9 the 5-year survival rate of NSCLC remains less than 18%.2 This evidence concerns the gene EGFR and non-small cell lung carcinoma.